Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women (18-70 years old)~* Body mass index \>27kg/m2~* Triglyceride levels ≤354 mg/dl and LDL chol ≤175 mg/dl~* No history of medication use for hepatic steatosis~* Increased liver fat (\>5.5%)~Exclusion Criteria:~* Inability or unwillingness to give written informed consent~* Systolic blood pressure \>160 mm Hg and/or diastolic blood pressure \> 105 mm Hg~* Type 1 or type 2 diabetes~* Chronic liver disease other than NAFLD (i.e. chronic infection with hepatitis C virus \[HCV\] or hepatitis B virus \[HBV\], autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson s disease, alpha-1 antitrypsin deficiency).~* Previous gastric or small bowel surgery~* Active gastric ulcer~* Inflammatory bowel disease~* ALT or AST \>3× ULN (upper limit of normal)~* Detection of cirrhosis by transient elastography or other imaging modalities~* Diarrhea (defined as more than 2 stool per day) within 7 days before enrollment~* Chronic kidney disease with an estimated glomerular filtration rate \<60 ml/min/1.73m2~* Significant cardiovascular co-morbidity (i.e. heart failure, documented coronary artery disease, valvular heart disease)~* Patients with active bronchial asthma~* Patients with phenylketonuria (contraindicated for NAC)~* Patients with histamine intolerance~* Clinically significant TSH level outside the normal range (0.04-6 mU/L)~* Known allergy for substances used in the study~* Concomitant medication use:~  1. Lipid-lowering drugs within 3 months~ 2. Oral antidiabetics given for insulin resistance of obesity (metformin, liraglutide etc.) within 3 months~ 3. Thiazide diuretics with a dose \>25 mg/d~ 4. Postmenopausal estrogen therapy~ 5. Any medication acting on nuclear hormone receptors or inducing Cytochromes P450 (CYPs)~ 6. Self-administration of dietary supplements such as any vitamins, omega-3 products, or plant stanol/sterol products within 1 month~ 7. Treatment with medications known to cause fatty liver disease such as atypical neuroleptics, tetracycline, methotrexate or tamoxifen~ 8. Use of an antimicrobial agent in the 4 weeks preceding randomization~* Active smokers consuming \>10 cigarettes/day~* Alcohol consumption over 192 grams for men and 128 grams for women per week~* Patients considered as inappropriate for this study for any reason (patients unable to undergo MRI study, noncompliance etc.)~* Subjects with Patatin-like phospholipase domain-containing protein 3( PNPLA3) I148M (homozygous for I148M)~* Women who are pregnant, are planning pregnancy, or who are breast-feeding~* Women of childbearing potential not protected by effective birth control method~* Active participation in another clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Subjects will take a mixture of placebo as powder dissolved in water by mouth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete